USMLE Step 3 Quiz: Chronic Kidney Disease Management
20 questions · exam conditions
0:00
Chronic Kidney Disease ManagementQuestion 1 of 20

eGFR 18, Hb 9.0, ferritin 120, TSAT 12%. Before epoetin, give?

Folic acid 1 mg daily
Iron replacement therapy
Vitamin B12 1 mg daily
Erythropoietin promptly
← Back to quizzes

USMLE Step 3 Quiz

USMLE Step 3 Quiz: Chronic Kidney Disease Management

Practice Chronic Kidney Disease Management in USMLE Step 3 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Chronic Kidney Disease Management, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

eGFR 18, Hb 9.0, ferritin 120, TSAT 12%. Before epoetin, give?

  1. Folic acid 1 mg daily
  2. Iron replacement therapy (correct answer)
  3. Vitamin B12 1 mg daily
  4. Erythropoietin promptly
Explanation: Low TSAT (12%) with ferritin 120 points to functional iron deficiency in CKD, so iron must be replaced before epoetin. Starting erythropoietin before iron stores are adequate blunts the response and increases cardiovascular risk. Folic acid and B12 are not indicated without deficiency; the tempting choice is giving erythropoietin promptly, but it will not work well until iron is repleted.

Question 2

eGFR 11, no uremic symptoms, wants hemodialysis. Best?

  1. Start urgent hemodialysis
  2. Plan arteriovenous fistula (correct answer)
  3. Repeat labs in 6 months
  4. Start very-low-protein diet
Explanation: An eGFR of 11 means kidney failure, but without uremic symptoms or emergency complications there is time to prepare access, not start urgent dialysis. The best next step is to plan an arteriovenous fistula so it can mature before dialysis is needed. Starting urgent hemodialysis now is the tempting choice but is wrong because urgent dialysis is reserved for life-threatening issues, not for patient request alone.

Question 3

eGFR 23, serum phosphate 6.0, calcium 8.2, PTH 190. First step?

  1. Dietary phosphate restriction (correct answer)
  2. Calcitriol 0.25 mcg every day
  3. Sevelamer 800 mg with meals
  4. Cinacalcet 30 mg every day
Explanation: At eGFR 23 with phosphate 6.0, calcium 8.2, and PTH 190, the first step is dietary phosphate restriction. You need to lower phosphate intake before adding binders or active vitamin D. Sevelamer is the tempting choice because it binds dietary phosphate, but it is not first-line until diet alone fails. Calcitriol can increase phosphate and is not the initial step.

Question 4

eGFR 28, elective CT with IV contrast. Best preventive measure?

  1. N-acetylcysteine 1200 mg BID
  2. Withhold lisinopril 48 hours
  3. Normal saline IV 1 mL/kg/h (correct answer)
  4. Furosemide 40 mg before CT
Explanation: With eGFR 28, the main risk is contrast-induced AKI, and isotonic IV saline at 1 mL/kg/h before and after contrast is the proven preventive measure. N-acetylcysteine is tempting but high-quality data show it does not reduce AKI risk, so fluid expansion with normal saline is the standard of care.

Question 5

A 66-year-old man has CKD stage 5 for 9 years from diabetes; he is stable and not on dialysis. He takes insulin, carvedilol 12.5 mg twice daily, amlodipine 10 mg daily, torsemide 40 mg daily, and sevelamer with meals. He reports decreased appetite and mild nausea but no dyspnea or confusion. BP is 148/84 mm Hg. Exam shows 1+ edema. Labs: creatinine 6.2 mg/dL, eGFR 9 mL/min/1.73 m², K 5.1 mEq/L, HCO3 18 mEq/L, Ca 8.6 mg/dL, phosphate 6.4 mg/dL, Hgb 10.1 g/dL. Renal ultrasound shows small echogenic kidneys. Which referral is most appropriate for this patient?

  1. Nephrology for renal replacement therapy education and planning (correct answer)
  2. Cardiology for routine stress testing before dialysis
  3. Gastroenterology for endoscopy to evaluate nausea
  4. Urology for cystoscopy to evaluate CKD progression
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based referral timing for renal replacement therapy in advanced CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's eGFR of 9 and uremic symptoms indicate the need for predialysis education and planning. The correct choice, nephrology for renal replacement therapy education and planning, accurately reflects current guidelines for managing CKD stage 5, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest cardiology for stress testing, which is not routinely required, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for dialysis initiation, regularly review eGFR trends, and practice identifying indications for specialist referral.

Question 6

A 70-year-old man with chronic kidney disease stage G4 (eGFR 22 mL/min/1.73m²) reports generalized fatigue and muscle weakness. His laboratory results show a serum bicarbonate level of 18 mEq/L. Physical examination is otherwise unremarkable.

  1. Initiate oral sodium bicarbonate supplementation. (correct answer)
  2. Encourage a diet high in protein to improve muscle strength.
  3. Administer a bolus of intravenous normal saline.
  4. Advise an increased intake of citrus fruits and juices.
Explanation: The patient has metabolic acidosis, a common complication of advanced CKD. Guidelines recommend treating metabolic acidosis with oral alkali supplementation (e.g., sodium bicarbonate) when the serum bicarbonate level is persistently below 22 mEq/L. Treatment can slow the progression of CKD, improve nutritional status, and alleviate symptoms like fatigue.

Question 7

A 68-year-old man with end-stage renal disease (eGFR 8 mL/min/1.73m²) presents to the emergency department with sharp, pleuritic chest pain that improves when he leans forward. He has missed his last three scheduled dialysis sessions. On examination, a triphasic friction rub is heard over the precordium. ECG shows diffuse, concave-up ST-segment elevations and PR depression. Blood pressure is 110/70 mmHg.

  1. Administer high-dose ibuprofen.
  2. Perform urgent pericardiocentesis.
  3. Initiate urgent hemodialysis. (correct answer)
  4. Administer colchicine and corticosteroids.
Explanation: The clinical presentation of pleuritic chest pain, a pericardial friction rub, and diffuse ST elevations in a patient with end-stage renal disease who has missed dialysis is classic for uremic pericarditis. This is an absolute and urgent indication for the initiation of renal replacement therapy. The definitive treatment is hemodialysis to remove the uremic toxins causing the inflammation. Pericardiocentesis is only indicated for tamponade.

Question 8

A 55-year-old man has CKD stage 3b for 4 years due to diabetes and hypertension; he exercises and limits sodium. Medications include metformin 1,000 mg twice daily, glyburide 5 mg daily, lisinopril 20 mg daily, and atorvastatin 40 mg nightly. He has no hypoglycemia awareness issues but reports two recent episodes of lightheadedness before lunch. BP is 124/70 mm Hg. Labs: creatinine 2.0 mg/dL, eGFR 32 mL/min/1.73 m², K 4.5 mEq/L. Which medication adjustment is most appropriate for this patient?

  1. Discontinue glyburide and use glipizide instead (correct answer)
  2. Increase glyburide dose to overcome insulin resistance
  3. Increase metformin dose despite reduced eGFR
  4. Stop lisinopril to prevent hypoglycemia episodes
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based adjustments for hypoglycemic agents in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hypoglycemia episodes and use of long-acting sulfonylurea indicate the need to switch to a shorter-acting agent. The correct choice, discontinuing glyburide and using glipizide instead, accurately reflects current guidelines for managing diabetes in CKD stage 3b, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest increasing glyburide, which worsens hypoglycemia risk, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for antidiabetic therapy in CKD, regularly review medication clearance, and practice recognizing drug-related adverse events.

Question 9

A 44-year-old man received a living-donor kidney transplant 3 years ago; he has stable function and takes tacrolimus, mycophenolate, and prednisone 5 mg daily. He also takes lisinopril for proteinuria and atorvastatin. He reports no symptoms. BP is 128/76 mm Hg. Labs: creatinine 1.6 mg/dL (baseline 1.6), eGFR 48 mL/min/1.73 m², K 5.8 mEq/L, HCO3 23 mEq/L, tacrolimus trough 7 ng/mL. Urinalysis shows trace protein. Ultrasound shows no obstruction. Which medication adjustment is most appropriate for this patient?

  1. Add patiromer while continuing lisinopril therapy (correct answer)
  2. Increase tacrolimus dose to improve graft perfusion
  3. Stop mycophenolate to correct hyperkalemia promptly
  4. Start spironolactone to lower potassium level
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based management of hyperkalemia in post-transplant patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hyperkalemia with RAAS inhibition indicates the need for a binder to preserve antiproteinuric therapy. The correct choice, adding patiromer while continuing lisinopril therapy, accurately reflects current guidelines for managing post-transplant CKD, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest stopping mycophenolate, which is unrelated to hyperkalemia, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for electrolyte management post-transplant, regularly review drug interactions, and practice optimizing immunosuppression with comorbidities.

Question 10

A 63-year-old man has CKD stage 4 for 6 years from diabetes; he follows low-sodium diet and takes losartan 100 mg daily, amlodipine 10 mg daily, insulin, and atorvastatin. He reports no symptoms. BP is 130/76 mm Hg. Exam shows mild pedal edema. Labs: creatinine 3.0 mg/dL, eGFR 20 mL/min/1.73 m², K 4.7 mEq/L, HCO3 22 mEq/L, Ca 8.8 mg/dL, phosphate 5.1 mg/dL, PTH 320 pg/mL. Which complication is this patient at highest risk for?

  1. Secondary hyperparathyroidism with renal osteodystrophy (correct answer)
  2. Acute uric acid nephropathy from tumor lysis
  3. Postrenal obstruction from benign prostatic hypertrophy
  4. Rapidly progressive glomerulonephritis with crescents
Explanation: This question tests chronic kidney disease management skills, specifically focusing on identifying risks for mineral bone disorder complications in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's elevated PTH and hyperphosphatemia indicate secondary hyperparathyroidism, increasing risk for bone disease. The correct choice, secondary hyperparathyroidism with renal osteodystrophy, accurately reflects current guidelines for recognizing CKD-MBD risks in stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest rapidly progressive GN, which is unlikely without acute changes, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for CKD complications, regularly review PTH and phosphate levels, and practice predicting long-term risks in renal patients.

Question 11

A 56-year-old woman has CKD stage 3b for 5 years from hypertension; she limits sodium and takes lisinopril 20 mg daily and amlodipine 10 mg daily. She develops chronic knee pain from osteoarthritis and asks about analgesics. BP is 124/76 mm Hg. Exam shows knee crepitus. Labs: creatinine 1.9 mg/dL, eGFR 37 mL/min/1.73 m², K 4.6 mEq/L. What is the next best step in managing this patient's CKD?

  1. Recommend acetaminophen and topical NSAID as needed (correct answer)
  2. Start daily oral naproxen for long-term control
  3. Start indomethacin because it is kidney-sparing
  4. Avoid all analgesics to prevent CKD progression
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based analgesic selection in CKD patients with osteoarthritis. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's chronic pain and CKD indicate the need for kidney-safe options like acetaminophen and limited topical NSAIDs. The correct choice, recommending acetaminophen and topical NSAID as needed, accurately reflects current guidelines for managing pain in CKD stage 3b, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest daily oral naproxen, which risks worsening renal function, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for analgesia in CKD, regularly review nephrotoxic agents, and practice balancing pain control with renal safety.

Question 12

A 69-year-old woman has CKD stage 5 for 11 years from diabetic nephropathy; she is stable and not yet on dialysis. She takes insulin, amlodipine 10 mg daily, torsemide 80 mg daily, sevelamer, and sodium bicarbonate. She reports mild anorexia but no dyspnea or pericardial pain. BP is 146/82 mm Hg. Exam shows 1+ edema. Labs: creatinine 6.8 mg/dL, eGFR 7 mL/min/1.73 m², K 5.2 mEq/L, HCO3 19 mEq/L, Ca 8.4 mg/dL, phosphate 6.1 mg/dL. Which referral is most appropriate for this patient?

  1. Vascular surgery for arteriovenous fistula evaluation (correct answer)
  2. Pulmonology for baseline pulmonary function testing
  3. Neurology for screening electroencephalography evaluation
  4. Orthopedics for prophylactic fracture risk assessment
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based referral for vascular access in predialysis CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's eGFR of 7 and uremic symptoms indicate imminent need for dialysis, requiring access planning. The correct choice, vascular surgery for arteriovenous fistula evaluation, accurately reflects current guidelines for managing CKD stage 5, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest pulmonology for PFTs, which is not routinely needed, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for dialysis preparation, regularly review access options, and practice timing referrals for advanced CKD.

Question 13

A 52-year-old man has CKD stage 3a for 3 years from type 2 diabetes and hypertension; he has worked on weight loss and limits sodium. Medications are metformin 500 mg twice daily, empagliflozin 10 mg daily, lisinopril 10 mg daily, and rosuvastatin 20 mg nightly. He has no dyspnea, edema, or urinary symptoms. BP is 122/70 mm Hg. Exam is normal. Labs: creatinine 1.4 mg/dL, eGFR 56 mL/min/1.73 m², K 4.6 mEq/L, HCO3 24 mEq/L. Urine albumin-to-creatinine ratio is 980 mg/g on two occasions. HbA1c is 7.4%. Renal ultrasound 2 years ago is normal. What is the next best step in managing this patient's CKD?

  1. Add finerenone for persistent albuminuria (correct answer)
  2. Stop empagliflozin due to CKD progression risk
  3. Switch lisinopril to hydrochlorothiazide for proteinuria
  4. Start high-protein diet to prevent sarcopenia
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based treatment strategies for persistent albuminuria in diabetic CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's high albumin-to-creatinine ratio despite SGLT2 and ACE inhibition indicates the need for additional antiproteinuric therapy. The correct choice, adding finerenone for persistent albuminuria, accurately reflects current guidelines for managing CKD stage 3a in diabetes, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest stopping empagliflozin, which is contraindicated as it provides cardiorenal protection, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for proteinuria management in CKD, regularly review emerging therapies like mineralocorticoid antagonists, and practice interpreting urine albumin levels in diabetic patients.

Question 14

A 71-year-old man has CKD stage 4 for 5 years from hypertension; he is stable and follows a renal diet. Medications include losartan 100 mg daily, amlodipine 10 mg daily, and furosemide 40 mg daily. He reports no symptoms. BP is 132/78 mm Hg. Labs: creatinine 3.1 mg/dL, eGFR 21 mL/min/1.73 m², Ca 8.6 mg/dL, phosphate 5.4 mg/dL, PTH 380 pg/mL, 25-hydroxyvitamin D 28 ng/mL. What is the next best step in managing this patient's CKD?

  1. Initiate dietary phosphate restriction and phosphate binder (correct answer)
  2. Start high-dose calcium supplements without monitoring
  3. Begin immediate dialysis for elevated phosphate level
  4. Stop losartan to reduce PTH secretion
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based interventions for mineral bone disorder in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hyperphosphatemia and elevated PTH indicate the need for phosphate control to prevent further complications. The correct choice, initiating dietary phosphate restriction and phosphate binder, accurately reflects current guidelines for managing CKD stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest immediate dialysis, which is premature without uremic symptoms, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for phosphate management, regularly review CKD-MBD labs, and practice stepwise approaches to bone-mineral disorders.

Question 15

A 72-year-old woman has CKD stage 4 for 8 years from hypertension; she is managed with diet and medications. Current medications include lisinopril 10 mg daily, amlodipine 5 mg daily, furosemide 20 mg daily, and calcium carbonate as needed for reflux. She reports constipation and pruritus. BP is 142/82 mm Hg. Exam shows excoriations and mild edema. Labs: creatinine 3.2 mg/dL, eGFR 19 mL/min/1.73 m², Ca 9.7 mg/dL, phosphate 6.0 mg/dL, PTH 410 pg/mL. Which medication adjustment is most appropriate for this patient?

  1. Switch calcium carbonate to sevelamer with meals (correct answer)
  2. Add calcitriol as first-line phosphate binder
  3. Stop furosemide to reduce phosphate retention
  4. Increase dietary phosphate intake to correct pruritus
Explanation: This question tests chronic kidney disease management skills, specifically focusing on evidence-based phosphate binder selection in CKD patients. Chronic kidney disease management involves regular monitoring of renal function, adjusting medications based on kidney status, and managing complications like anemia and electrolyte imbalances. In the presented vignette, the patient's hypercalcemia from calcium carbonate indicates the need for a non-calcium binder to control phosphate. The correct choice, switching calcium carbonate to sevelamer with meals, accurately reflects current guidelines for managing hyperphosphatemia in CKD stage 4, demonstrating the student's understanding of appropriate clinical interventions. A common distractor may suggest adding calcitriol first, which can worsen hypercalcemia, highlighting a frequent misconception. To improve understanding, students should focus on guidelines for CKD-MBD therapy, regularly review binder side effects, and practice selecting agents based on lab profiles.

Question 16

A 59-year-old woman with CKD stage G4 (eGFR 25 mL/min/1.73m²) due to lupus nephritis is seen for routine follow-up. Her immunizations are up to date, including her annual influenza vaccine. She is clinically stable on her immunosuppressive regimen. As she is approaching the need for renal replacement therapy, which vaccination is most important to administer at this time?

  1. Hepatitis B vaccine series (correct answer)
  2. Herpes zoster vaccine (recombinant)
  3. Human papillomavirus vaccine
  4. Measles, mumps, and rubella vaccine
Explanation: Patients with advanced CKD who are likely to require dialysis are at increased risk of acquiring hepatitis B infection. Furthermore, their immune response to vaccination is often blunted, and the response is better before the initiation of dialysis. Therefore, administering the hepatitis B vaccine series is a high priority in the pre-ESRD population. While other vaccines are important, the Hepatitis B series has unique urgency in this clinical context.

Question 17

A 60-year-old man with CKD stage G4 (eGFR 24 mL/min/1.73m²) has the following laboratory results: phosphorus 4.6 mg/dL, calcium 9.0 mg/dL, intact PTH 150 pg/mL (normal 15-65 pg/mL), and 25-hydroxyvitamin D 15 ng/mL (deficient <20 ng/mL). What is the most appropriate initial intervention for his mineral and bone disease?

  1. Initiate a non-calcium phosphate binder like sevelamer.
  2. Initiate a calcimimetic such as cinacalcet.
  3. Initiate an active vitamin D analog like calcitriol.
  4. Initiate nutritional vitamin D supplementation with ergocalciferol. (correct answer)
Explanation: This patient has secondary hyperparathyroidism and vitamin D deficiency. The initial step in management is to correct the nutritional vitamin D deficiency with ergocalciferol (D2) or cholecalciferol (D3). Repleting vitamin D stores can help lower PTH levels. Active vitamin D analogs like calcitriol are typically reserved for more severe hyperparathyroidism in later-stage CKD, especially in dialysis patients, and are used after nutritional vitamin D is replete. His phosphorus is only minimally elevated, not warranting a binder at this time.

Question 18

A 58-year-old woman with diabetic nephropathy and CKD stage G3b (eGFR 40 mL/min/1.73m²) is on maximally tolerated lisinopril and dapagliflozin. Her blood pressure is 125/78 mmHg. Despite these therapies, her urine albumin-to-creatinine ratio remains elevated at 500 mg/g. Her serum potassium is 5.1 mEq/L. Which medication would be the most appropriate addition to further reduce her risk of CKD progression?

  1. Add losartan to the lisinopril.
  2. Add spironolactone.
  3. Add finerenone. (correct answer)
  4. Add hydralazine.
Explanation: For patients with diabetic kidney disease who have persistent albuminuria despite treatment with an ACE inhibitor or ARB and an SGLT2 inhibitor, adding a non-steroidal mineralocorticoid receptor antagonist (MRA) like finerenone is indicated. Finerenone has been shown in large clinical trials to reduce the risk of CKD progression and cardiovascular events in this population. Dual RAAS blockade (ACEi + ARB) is contraindicated. While spironolactone is also an MRA, finerenone has a better side-effect profile regarding hyperkalemia and has specific outcome data for this indication.

Question 19

A randomized controlled trial investigated the effect of a new drug, renoprotectin, versus placebo in 2000 patients with CKD stage 3-4 and type 2 diabetes, already treated with an ACE inhibitor. The primary endpoint was a composite of a 40% decline in eGFR, end-stage renal disease, or death from renal or cardiovascular causes. Over 3 years, the primary endpoint occurred in 15% of the renoprotectin group and 20% of the placebo group (Hazard Ratio 0.75; 95% CI 0.60-0.94; p=0.01). Hyperkalemia (K+ > 5.5 mEq/L) occurred in 18% of the renoprotectin group versus 9% in the placebo group.

Based on this abstract, which of the following is the most accurate conclusion?

  1. Renoprotectin is a safe and effective treatment for all patients with chronic kidney disease.
  2. The benefit of renoprotectin does not outweigh its risks because the p-value is greater than 0.001.
  3. The study demonstrates that renoprotectin prevents the need for dialysis in patients with CKD.
  4. Renoprotectin reduces the risk of the primary composite endpoint but increases the risk of hyperkalemia. (correct answer)
Explanation: The abstract shows a statistically significant reduction in the primary composite endpoint (HR 0.75, 95% CI does not cross 1.0, p=0.01). This indicates the drug is effective. However, it also shows a doubling of the rate of hyperkalemia. Therefore, the most accurate conclusion is that the drug reduces major adverse events but at the cost of an increased risk of hyperkalemia. The other options are inaccurate generalizations or misinterpretations of the statistical data.

Question 20

An 84-year-old man with severe dementia, end-stage renal disease (eGFR 11 mL/min/1.73m²), and advanced heart failure is brought to the office by his daughter, who is his healthcare proxy. He is increasingly lethargic with poor appetite. His advance directive states he would not want "life-prolonging procedures" if he had a "terminal condition with no hope of recovery." The daughter asks if her father should start dialysis.

  1. "Dialysis is the standard treatment, so we should schedule him for access placement right away."
  2. "His advance directive is clear, so we are legally unable to offer him dialysis treatment."
  3. "We can start with a trial of dialysis for a few weeks and stop if there's no improvement."
  4. "Let's talk about your father's current condition and what your goals are for his care at this stage." (correct answer)
Explanation: When you encounter questions about end-of-life care decisions, focus on patient-centered communication and shared decision-making rather than making unilateral medical recommendations. These scenarios test your understanding of how to navigate complex ethical situations involving advance directives, family dynamics, and goals of care. The correct approach here is option D because it opens a dialogue to explore the family's understanding of the patient's condition, clarify his values and preferences, and discuss realistic treatment goals. This patient has multiple end-stage conditions (severe dementia, ESRD, advanced heart failure) that collectively suggest a very poor prognosis. Before making any treatment decisions, you need to understand what "life-prolonging procedures" and "terminal condition" meant to this patient when he wrote his directive. Option A is wrong because it bypasses the ethical complexity and ignores the advance directive entirely. Starting dialysis without exploring goals of care could violate the patient's wishes. Option B incorrectly suggests that advance directives create absolute legal barriers. While the directive provides guidance, it requires interpretation - does ESRD with multiple comorbidities constitute his envisioned "terminal condition"? Option C proposes a trial approach but still doesn't address the fundamental question of whether dialysis aligns with the patient's values and the family's goals for his care. For USMLE Step 3, remember that end-of-life scenarios prioritize communication and shared decision-making over immediate medical interventions. When advance directives are involved, your first step should always be exploring their meaning with the patient/family rather than making assumptions about what they permit or prohibit.